Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Penland Foundation has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 5 examiners and 4 art units, indicating broad examiner coverage with some concentration at the technical-unit level.
PAGUIO FRISING, MICHELLE F is the busiest examiner, with 1 pending matter. Counsel should coordinate recurring unit issues while retaining matter-specific strategies for the separate examiner assignments.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORGEEST, CHRISTINA M | 1 | 55.7% | +21.4% |
| ZEMAN, ROBERT A | 1 | 54.2% | +27.9% |
| GREENE, IVAN A | 1 | 18.8% | +6.1% |
| PAGUIO FRISING, MICHELLE F | 1 | 71.2% | +38.9% |
| CURRENS, GRANT CARSON | 1 | 54.9% | +60.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18392640 | TREATMENT OF DELIRIUM USING NITROUS OXIDE | GREENE, IVAN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17987653 | TREATMENT OF CARDIAC ARRHYTHMIA USING BOTULINUM TOXIN | CURRENS, GRANT CARSON | 31d overdue |
| 18392662 | TREATMENT OF ACUTE HEART FAILURE USING NITROUS OXIDE AND CHRONIC HEART FAILURE USING BOTULINUM TOXIN | PAGUIO FRISING, MICHELLE F | 21d |
| 18392590 | TREATMENT OF CANCER USING BOTULINUM TOXIN AND NITROUS OXIDE | ZEMAN, ROBERT A | 84d |
| 18392612 | TREATMENT OF THE DEMENTIAS USING BOTULINUM TOXIN | BORGEEST, CHRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 1651 | 2 |
| 1675 | 1 |
| 1645 | 1 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18392612 | TREATMENT OF THE DEMENTIAS USING BOTULINUM TOXIN | BORGEEST, CHRISTINA M | 1675 | §112 | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18392590 | TREATMENT OF CANCER USING BOTULINUM TOXIN AND NITROUS OXIDE | ZEMAN, ROBERT A | 1645 | §112Other | Non-Final OA | 84d | Pending | Dec 21, 2023 |
| 18392640 | TREATMENT OF DELIRIUM USING NITROUS OXIDE | GREENE, IVAN A | 1619 | §103§112 | Final Rejection | — | Pending | Dec 21, 2023 |
| 18392662 | TREATMENT OF ACUTE HEART FAILURE USING NITROUS OXIDE AND CHRONIC HEART FAILURE USING BOTULINUM TOXIN | PAGUIO FRISING, MICHELLE F | 1651 | §103Other | Final Rejection | 21d | Pending | Dec 21, 2023 |
| 17987653 | TREATMENT OF CARDIAC ARRHYTHMIA USING BOTULINUM TOXIN | CURRENS, GRANT CARSON | 1651 | §112DP | Final Rejection | 31d overdue | Pending | Nov 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPenland Foundation has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Christina M Borgeest has the most, with 1 of Penland Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
